Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Abstract Background The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII study primarily aimed to evaluate the efficacy and safety of saroglitazar (2 mg and 4 mg) as compared to pioglitaz...

Full description

Bibliographic Details
Main Authors: Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes mellitus
Saroglitazar
Peroxisome proliferator-activated receptors (PPAR α/γ) agonist
Pioglitazone
Cardiovascular disease risk
Online Access:http://link.springer.com/article/10.1186/s12933-020-01073-w

Internet

http://link.springer.com/article/10.1186/s12933-020-01073-w

Similar Items